GlassScriptPhysician profile
Alan G Peaslee
NPI 1346211281
$5,649.17
in general payments reported to CMS, 2019-2025
25 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $139 · 2021: $444 · 2022: $626 · 2023: $1,276 · 2024: $1,466 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,840.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $970.27 | 2022-2025 | |
| Glaukos Corporation | $666.22 | 2021-2025 | Kxl System (Not Refurbished), Istent Trabecular Micro-Bypass System Model Is3, Photrexa Viscous and Photrexa |
| Alcon Vision LLC | $503.80 | 2019-2025 | Acrysof Iq Vivity, Clareon, Precision7 |
| Sun Pharmaceutical Industries INC. | $434.52 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $347.34 | 2023-2024 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Vision Care, INC. | $344.44 | 2019-2023 | Acuvue |
| Allergan, INC. | $334.80 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $297.97 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Rxsight INC | $224.51 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Contact Lens |
| Horizon Therapeutics Plc | $219.99 | 2022-2023 | Uplizna |
| Biotissue Holdings INC. | $183.32 | 2023-2025 | |
| Sight Sciences, INC. | $168.61 | 2024 | Tearcare System, Omni Surgical System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $137.16 | 2019-2020 | |
| Astellas Pharma US INC | $133.56 | 2023 | |
| Dompe US, INC. | $124.99 | 2025 | Oxervate |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $122.11 | 2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $116.64 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $96.62 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $60.81 | 2019 | |
| Carl Zeiss Meditec, INC. | $55.56 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $29.95 | 2023 | Clarus |
| Kala Pharmaceuticals, INC. | $22.27 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $21.08 | 2024 | Tecnis Simplicity |
| Thea Pharma INC. | $16.43 | 2023 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $16.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Peaslee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.